Investor Relations Captor Therapeutics ®
Presentations & Posters
-
-
Publication date:
Captor Q3 2024 -
Publication date:
Captor Corporate Presentation 2024
-
Publication date:
Pioneering Targeted Protein Degraders For Human Health (Trigon Oct2024)
-
Publication date:
A New Modality for the Management of Inflammation: NEK7 Degradation
-
Publication date:
Captor H1 2024 Results
-
Publication date:
Captor Q1 2024
-
Publication date:
MCL-1: A Target with Immense Potential in Oncology
-
Publication date:
Captor Annual Report (April 2024)
-
Publication date:
Targeted Protein Degradation Q1 2024 Update
-
-
-
Publication date:
Investor Day 2023
-
Publication date:
Q3 2023 update
-
Publication date:
6th TPD Summit, Boston - poster
-
Publication date:
TPD 2023, Basel - poster
-
Publication date:
SLAS 2023, Warsaw - poster
-
Publication date:
Presentation of results for the first half of 2023
-
Publication date:
Presentation of results for the first quarter of 2023
-
Publication date:
Investor FactSheet FY2022
-
Publication date:
Captor Strategy Next Steps 2023-2025
-
-
-
Publication date:
Investor FactSheet Q3 2022
-
Publication date:
ESMO Asia Congress, Singapore -poster
-
Publication date:
ENA 2022, Barcelona - poster
-
Publication date:
5th Annual Targeted Protein Degradation Summit, Boston - poster
-
Publication date:
Corporate Presentation H1/2022
-
Publication date:
R&D Day
-
Publication date:
Investor Factsheet Q1 2022
-
Publication date:
Investor Day Presentation
-
Publication date:
CT-01 molecular target disclosure – what does this mean for project development?
-
Publication date:
2nd Annual Targeted Protein Degradation Europe Summit
-
Publication date:
Promising research results in two flagship projects
-